Eyeworld

Improved near and intermediate vision without compromising distance vision † 1 Go ahead. Read the fine print. V UIT Y ® MAY B E A B LE TO HELP. 1,2 In studies, VUITY ® improved the ability to read an additional 3 lines or more on a near vision eye chart.† AN E YE D RO P FO R PRESBYO PIA? 1,2 © 2022 AbbVie. All rights reserved. All trademarks are the property of their respective owners. US-VUI-220399 VuityPro.com/efficacy Not an actual patient INDICATION VUITY® (pilocarpine hydrochloride ophthalmic solution) 1.25% is indicated for the treatment of presbyopia in adults. IMPORTANT SAFETY INFORMATION CONTRAINDICATIONS VUITY is contraindicated in patients with known hypersensitivity to any ingredient in the formulation. WARNINGS AND PRECAUTIONS Miotics, including VUITY, may cause accommodative spasm. Patients should be advised not to drive or operate machinery if vision is not clear (e.g., blurred vision). In addition, patients may experience temporary dim or dark vision with miotics, including VUITY. Patients should be advised to exercise caution in night driving and other hazardous activities in poor illumination. Rare cases of retinal detachment and retinal tear have been reported with miotics, including VUITY. Individuals with pre-existing retinal disease are at increased risk. Therefore, examination of the retina is advised in all patients prior to the initiation of therapy. Patients should be advised to seek immediate medical care with sudden onset of flashing lights, floaters, or vision loss. VUITY is not recommended to be used when iritis is present because adhesions (synechiae) may form between the iris and lens. Contact lens wearers should be advised to remove their lenses prior to the instillation of VUITY and to wait 10 minutes after dosing before reinserting their contact lenses. To prevent eye injury or contamination, care should be taken to avoid touching the dispensing bottle to the eye or to any other surface. ADVERSE REACTIONS The most common adverse reactions (>5%) reported in clinical trials were headache and conjunctival hyperemia. Please see Brief Summary of full Prescribing Information on the accompanying page or reverse side. † Primary endpoint was the proportion of participants gaining ≥3 lines in mesopic, high-contrast, binocular, distance-corrected near visual acuity (DCNVA) without losing more than 1 line (5 letters) of corrected distance visual acuity (CDVA) with the same refractive correction at Day 30, Hour 3. 1 Change from baseline in photopic, high-contrast, binocular, DCIVA at Day 30, Hour 3 was a prespecified secondary endpoint. 3 References: 1. VUITY Prescribing Information. 2. Price FW, et al. Ophthalmol Sci. 2021; doi: https://doi.org/10.106/j.xops.2021.100065. 3. Data on File, ABVRRTI73127.

• Blank Page
• Blank Page (1)